SomnoMed (ASX:SOM) General and Admin. Expense: A$24.2 Mil (TTM As of Dec. 2025)


ASX:SOM SomnoMed Ltd ASX:SOM
51 GF Score
Price A$0.52
GF Value A$0.45
Valuation Modestly Overvalued
! 3 Warning Signs
View Full Analysis

What is SomnoMed General and Admin. Expense?

SomnoMed ASX:SOM -0.95% 51 General and Admin. Expense is A$24.2 Mil as of Dec. 2025. GuruFocus rates ASX:SOM with a GF Score™ of 51/100 and a GF Value™ of A$0.45 (Modestly Overvalued). The stock has 3 warning signs investors should review.

General and Admin. Expense is the aggregate total of general managing and administering expenses for the company. SomnoMed's General and Admin. Expense for the six months ended in Dec. 2025 was A$19.8 Mil. Its General and Admin. Expense for the trailing twelve months (TTM) ended in Dec. 2025 was A$24.2 Mil.

SomnoMed General and Admin. Expense Related Terms

SomnoMed General and Admin. Expense Historical Data

* Premium members only.

The historical data trend for SomnoMed's General and Admin. Expense can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

SomnoMed General and Admin. Expense Chart

SomnoMed Annual Data
Trend Jun16 Jun17 Jun18 Jun19 Jun20 Jun21 Jun22 Jun23 Jun24 Jun25
General and Admin. Expense
Get a 7-Day Free Trial Premium Member Only Premium Member Only 11.21 13.81 14.15 18.01 22.14

SomnoMed Semi-Annual Data
Jun16 Dec16 Jun17 Dec17 Jun18 Dec18 Jun19 Dec19 Jun20 Dec20 Jun21 Dec21 Jun22 Dec22 Jun23 Dec23 Jun24 Dec24 Jun25 Dec25
General and Admin. Expense Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only 15.98 2.03 17.74 4.40 19.77
ASX:SOM
51GF Score
SomnoMed Ltd ASX:SOM
General and Admin. Expense is just one metric. See GF Score™, valuation, warning signs, and more.
View Full Analysis

SomnoMed General and Admin. Expense Calculation

General and Admin. Expense is the aggregate total of general managing and administering expenses for the company.

General and Admin. Expense for the trailing twelve months (TTM) ended in Dec. 2025 adds up the semi-annually data reported by the company within the most recent 12 months, which was A$24.2 Mil.

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

What does a General and Admin. Expense of A$24.2 Mil mean?
SomnoMed (ASX:SOM) has a General and Admin. Expense of A$24.2 Mil as of Dec. 2025. General and Admin. Expense is the aggregate total of general managing and administering expenses for the company. View historical data on SomnoMed and its competitors.
Is SomnoMed's General and Admin. Expense too high?
SomnoMed's current General and Admin. Expense is A$24.2 Mil. Overall, SomnoMed has a GF Score™ of 51/100 and is considered Modestly Overvalued, reflecting its overall financial health beyond just this single metric.
How does SomnoMed's General and Admin. Expense compare to ABT and SYK?
SomnoMed's General and Admin. Expense of A$24.2 Mil can be compared against companies in the Medical Devices & Instruments industry. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good General and Admin. Expense for a Medical Devices & Instruments company?
A good General and Admin. Expense depends on the Medical Devices & Instruments industry context. However, General and Admin. Expense should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high General and Admin. Expense mean?
A high General and Admin. Expense can signal that a stock is expensive relative to its fundamentals. General and Admin. Expense is the aggregate total of general managing and administering expenses for the company. View historical data on SomnoMed and its competitors. SomnoMed's current General and Admin. Expense is A$24.2 Mil. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is SomnoMed stock overvalued right now?
Based on GuruFocus' analysis, SomnoMed (ASX:SOM) is currently considered Modestly Overvalued. The stock's GF Value™ is A$0.45, compared to a current price of A$0.52 — trading 15.6% above its estimated fair value. The current General and Admin. Expense is A$24.2 Mil. SomnoMed's overall GF Score™ is 51/100 with 3 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is General and Admin. Expense calculated?
General and Admin. Expense is calculated from a company's financial statements. For SomnoMed (ASX:SOM), the current General and Admin. Expense is A$24.2 Mil as of Dec. 2025. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.

Is SomnoMed (ASX:SOM) Overvalued in 2026?

Based on GuruFocus' analysis, SomnoMed stock appears to be overvalued. The current stock price of A$0.52 is trading 15.6% above its estimated GF Value™ of A$0.45. GuruFocus considers SomnoMed to be Modestly Overvalued.

Key valuation signals for ASX:SOM:

  • General and Admin. Expense: A$24.2 Mil
  • GF Value™: A$0.45 vs. price of A$0.52 (15.6% above fair value)
  • GF Score™: 51/100 with 3 warning signs

No single metric tells the full story. See the ASX:SOM stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.

SomnoMed Business Description

Other Exchanges SOMNF:USARJV:Germany
Address 20 Clarke Street, Level 3, Crows Nest, Sydney, NSW, AUS, 2065
SomnoMed Ltd provides treatment solutions for sleep-related breathing disorders, including obstructive sleep apnea, snoring, and bruxism. It is engaged in commercializing SomnoDent Mandibular Advancement Splint (MAS) and other oral devices for sleep-related disorders in Australia and overseas. The other products in the company's portfolio include SomMorning Repositioner; SomnoBrux splint, a custom-fit, acrylic splint (dental guard) for upper teeth designed to protect teeth from grinding and scraping during Bruxism; and SomTabs cleaning tablets that have been developed to clean oral appliances. Geographically, the company generates maximum revenue from Europe, followed by North America and the Asia Pacific region.
51GF Score

Get the complete analysis for ASX:SOM

General and Admin. Expense is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.

A$0.52
Price
A$0.45
GF Value